Analysts at Noble Capital reiterate 'Outperform' rating and $5 price target on GenprexProactive Investors • 08/16/22
Genprex announces US patent for REQORSA Immunogene Therapy in combination with immune checkpoint inhibitors to treat cancersProactive Investors • 08/16/22
Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat CancersPRNewsWire • 08/16/22
Genprex secures higher dose approval for REQORSA in combination with Tagrisso Phase 1 clinical trialProactive Investors • 08/15/22
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung CancerPRNewsWire • 08/15/22
Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery SummitPRNewsWire • 07/13/22
Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress ConferencePRNewsWire • 05/09/22
Genprex CEO shares key progress for non-small cell lung cancer treatment REQORSA in shareholder letterProactive Investors • 05/05/22
Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022PRNewsWire • 04/18/22
Genprex announces opening of patient enrollment for its Acclaim-2 clinical trialProactive Investors • 03/31/22
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung CancerBusiness Wire • 03/31/22
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerBusiness Wire • 03/02/22
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and DiabetesBusiness Wire • 02/09/22
Genprex says preclinical data shows potential for ONCOPREX Nanoparticle Delivery System in treating colon cancerProactive Investors • 01/27/22
Preclinical Data Show Potential for Use of Genprex's ONCOPREX® Nanoparticle Delivery System in Treating Colon CancerBusiness Wire • 01/27/22
Genprex says it plans to ramp up opening of its Acclaim-1 clinical trial sitesProactive Investors • 01/10/22
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung CancerBusiness Wire • 01/10/22
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company's Gene Therapies in Cancer and DiabetesBusiness Wire • 01/05/22